Personalized treatment for advanced solid tumors using tumor genetics and expression profiling
Official title: A Prospective Study Using Genomic Screening to Select Patients for Targeted Molecular Treatment
Run by Copenhagen University Hospital, Rigshospitalet · NCT02290522 · Data updated 2026-11-12
This study tests whether a patient’s tumor genetics and gene expression can guide personalized treatment choices for adults with advanced solid tumors.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Copenhagen University Hospital, Rigshospitalet Academic / other |
| Locations | 1 site (Copenhagen) |
| Status | Recruiting |
| Started | May 1, 2013 |
| Main results expected | December 31, 2028 |
| Study ends | December 31, 2029 |
| Registry record updated | August 12, 2026 |
| Trial ID | NCT02290522 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with an unresectable or progressed solid tumor, with no standard treatment option, measurable disease, good performance status (PS 0-1), and consent to biopsy.
✕Probably not a fit
Patients whose tumors lack actionable genetic targets or who cannot tolerate targeted therapies may not experience benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Patients with advanced solid tumors referred to the Phase 1 Unit undergo a comprehensive molecular workup, including tumor DNA and RNA profiling, to identify targets for existing or developing drugs. The approach uses SNP-array, whole exome sequencing of tumor and blood, expression arrays, and RNA sequencing to explore genetic alterations and tumor expression patterns. A tumor board reviews results to match patients with targeted therapies, and progression-free survival is compared to the patient’s most recent standard treatment to gauge benefit.
Why it matters
Potential benefit: If successful, patients may receive a targeted therapy tailored to their tumor’s molecular profile, potentially improving outcomes.
How similar studies have gone: Prior studies using integrated genomic and expression profiling have shown potential in guiding targeted therapies, though results vary by cancer type and target.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Solid tumor * No standard treatment option * PS 0-1 * Lesion assessable for biopsy * Measurable disease * Informed consent Exclusion Criteria: * Life expectancy \< 3 months * Bone marrow suppression * Abnormal renal or hepatic function * Serious concurrent medical conditions
Where it's running
-
Rigshospitalet
Copenhagen, Denmark Recruiting
Study contacts
- Principal investigator: Ulrik Lassen, MD, PH.D. — Copenhagen University Hospital, Rigshospitalet
- Study coordinator: Ida V Tuxen, MD
- Phone: +4535453545
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing CP-506 for treating advanced solid tumors
This study is testing a new drug called CP-506 to see if it can help people with advanced solid tumors, especially those with specific DNA repair issues, by trying it alone and with other treatments.
-
Using genomic profiling to recommend cancer treatment for patients with metastatic tumors
This study tests if analyzing the DNA of metastatic tumors can help doctors recommend better treatments for cancer patients.
-
Registry of older patients with cancer
This study collects health information from older cancer patients to create a registry that helps improve care and research for seniors with cancer.
-
Collecting tissue samples from cancer patients and healthy participants
This study is collecting tissue samples from cancer patients receiving radiation therapy and healthy individuals to see how genetic differences affect treatment outcomes and to build a resource for future research.
-
Collecting and storing tissue samples from patients with suspected solid tumors
This study is collecting blood and tissue samples from patients with suspected solid tumors to help with future cancer research and understand how normal tissue changes to cancerous tissue.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.